Viewing nowCombinationDangi Ja Nookombi Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Myeongmun Pharmaceutical Co., Ltd.

MFDS item code 202200404 · Approved 2022.01.24 · Insurance code 649807950
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It is used in cases where patients have not previously received any diabetes drug treatment or when blood sugar control is difficult with monotherapy. It can also be administered when sufficient efficacy is not achieved with monotherapy of metformin or sitagliptin. If blood sugar control is challenging with combinations of metformin and sulfonylureas, or metformin and thiazolidinediones, this medication can be used in conjunction. It is also administered if blood sugar is not well controlled with insulin and metformin therapy, to improve blood sugar management. This medication helps with blood sugar control across various treatment stages.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Use This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medicine).
This medication contains sitagliptin and metformin and is used for treating diabetes. First, there is a risk of severe allergic reactions within the first three months of administration, so caution is needed. If symptoms such as rash, shortness of breath, or swelling of the face or neck occur, discontinue use immediately and consult a doctor. This medication may cause acute pancreatitis, which is a serious inflammation of the pancreas; if symptoms such as abdominal pain, nausea, or vomiting occur, inform healthcare personnel immediately. The metformin component can cause a rare but serious metabolic disturbance called lactic acidosis, so patients with severe dehydration, infections, heart diseases, liver diseases, or impaired renal function should not take this medication. Patients with moderate or more severe renal impairment, acute heart failure, or those scheduled for tests using iodine contrast agents should not take this medication. It is not safe for use during pregnancy or breastfeeding, or in children and adolescents under 18 years, as safety has not been established. During treatment, it is important to regularly monitor kidney function and blood tests, as vitamin B12 levels may need to be checked because of the risk of deficiency. Also, this medication may induce hypoglycemia, so caution is advised when skipping meals or engaging in vigorous exercise, and be aware that the risk of hypoglycemia may increase when taking it together with other hypoglycemic agents such as insulin or sulfonylureas. Alcohol consumption can increase the risk of lactic acidosis, so avoid excessive drinking while on this medication. Before and after surgery, discontinue this medication for a period of time and restart it only after the patient’s condition stabilizes. Rarely, this medication can cause severe joint pain or the formation of blisters on the skin, so if such symptoms occur, inform a doctor immediately and seek treatment. Finally, regular monitoring of blood sugar and kidney function is crucial during treatment, and immediately consult healthcare personnel if unusual symptoms arise.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and it is safe to keep it at a temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medicine's effectiveness for a longer period.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Myeongmun Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.